Diagnostic accuracy of 13 N-ammonia PET, 11 C-methionine PET and 18 F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Qiao He; Linqi Zhang; Bing Zhang; Xinchong Shi; Chang Yi; Xiangsong Zhang

doi:10.1186/s12885-019-5560-1

Table 2 Details of patient characteristics, results of each PET imaging, and reference criteria for the final diagnosis in patients with non-glioma tumors and non-neoplastic lesions

From: Diagnostic accuracy of ¹³N-ammonia PET, ¹¹C-methionine PET and ¹⁸F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Pt. No.	Age range (y)	Location^a	FDG		NH₃		MET		Method of diagnosis	Final diagnosis
Pt. No.	Age range (y)	Location^a	Visual	L/WM^b	Visual	L/WM	Visual	L/WM	Method of diagnosis	Final diagnosis
Non-glioma tumors
1	50–55	Cerebellum	(+)	2.24	(+)	1.72	(+)	2.89	Operation	Metastatic adenocarcinoma
2	20–25	L. basal ganglia region	(−)	1.32	(+)	2.67	(+)	3.24	Biopsy	Germinoma
3	35–40	R. cavernous sinus area	(+)	2.38	(+)	2.30	(+)	3.35	Operation	Squamous cell carcinoma
4	40–45	Suprasellar	(−)	1.07	(+)	2.42	(+)	2.28	Operation	Craniopharyngioma
5	65–70	R. parietal	(−)	1.37	(+)	3.75	(+)	2.72	Operation	Meningioma
6	60–65	Cerebellum	(−)	1.28	(+)	3.66	(+)	2.78	Operation	Hemangioblastoma
7	25–30	Cerebellum	(+)	2.61	(+)	2.00	(+)	2.00	Operation	Medulloblastoma
8	25–30	Cerebellum	(+)	2.32	(+)	2.40	(+)	2.24	Operation	Medulloblastoma
9	45–50	L. frontal	(+)	4.02	(+)	3.09	(+)	3.00	Operation	Metastatic tumor
10	30–35	R. frontal	(−)	1.22	(−)	1.60	(+−)	1.51	Operation	DNT
Non-neoplastic lesions
11	20–25	L. frontal	(+)	2.75	(+−)	1.68	(+−)	1.58	Follow-up	Inflammation
12	40–45	L. frontal-parietal	(−)	1.76	(−)	1.10	(−)	1.00	Biopsy	Demyelination
13	30–35	R. parietal	(+−)	2.10	(+−)	1.64	(+)	2.27	Follow-up	Demyelination
14	25–30	R. basal ganglia region	(+−)	2.12	(+−)	1.72	(+−)	1.50	Biopsy	Demyelination
15	70–75	Cervical spinal	(+)	2.88	(+−)	1.70	(+−)	1.78	Follow-up	Inflammation
16	20–25	R. cerebellopontine angle	(−)	1.32	(+−)	1.63	(+−)	1.55	Follow-up	Demyelination
17	25–30	R. thalamus	(−)	1.80	(+−)	1.75	(+−)	1.77	Follow-up	Inflammation
18	40–45	R. parietal	(+)	2.23	(+−)	1.72	(+)	2.49	Biopsy	Inflammation
19	35–40	R. cerebellum	(+)	2.80	(−)	1.45	(−)	1.38	Follow-up	Inflammation
20	40–45	Brain stem, R. temporal	(−)	1.58	(−)	1.55	(+−)	1.54	Follow-up	Inflammation
21	40–45	L. pons	(−)	1.56	(−)	1.29	(−)	1.31	Follow-up	Infarction
22	50–55	L. temporal	(+)	2.49	(−)	0.94	(+)	2.67	Operation	Brain abscess
23	45–50	L. parietal	(+)	3.28	(−)	1.63	(+)	2.88	Operation	Brain abscess
24	40–45	R. frontal	(+)	3.80	(−)	1.58	(+)	3.04	Operation	Brain abscess
25	20–25	L. parietal	(−)	1.10	(−)	1.18	(−)	1.32	Biopsy	Demyelination
26	30–35	L. basal ganglia region	(−)	1.44	(−)	1.45	(−)	1.40	Follow-up	Multiple sclerosis
27	40–45	R. cerebellum	(−)	1.98	(+−)	1.79	(+)	2.60	Follow-up	Infarction
28	50–55	L. frontal	(+−)	2.10	(+−)	1.75	(+)	1.95	Biopsy	Inflammation
29	78–80	R. parietal	(−)	1.06	(−)	1.14	(+)	1.86	Follow-up	Hemorrhage
30	40–45	L. frontal and parietal	(+)	2.70	(+)	1.87	(+)	3.15	Biopsy	Inflammation
31	40–45	Pons	(−)	1.68	(−)	1.54	(−)	1.38	Follow-up	Brain abscess
32	50–55	R. basal ganglia region	(−)	1.58	(−)	1.02	(+)	1.81	Follow-up	Infarction
33	25–30	L. thalamus	(−)	1.52	(−)	1.44	(−)	1.15	Biopsy	Demyelination

^a R right, L left, ^b L/WM Lesion-to-white matte ratio, DNT dysembryoplastic neuroepithelial tumor

Back to article page